Protein / target

Interleukin-17D

Encoded byIL17DQ8TAD2Homo sapiensSwiss-Prot

UniProt: Q8TAD2 Ensembl: ENSG00000172458 HGNC: HGNC:5984 NCBI Gene: 53342

Antibody-tractable

Druggability

UniProt loc med conf

Research papers

Protein at a glance

Biological role

Protein homodimerization

Strongest disease association

Intelligence

Via encoding gene IL17D · Genetic evidence · score 0.12

Research activity

Emerging research

3 papers · latest 2024

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Induces expression of IL6, CXCL8/IL8, and CSF2/GM-CSF from endothelial cells

Subcellular location

Secreted

Domains and Gene Ontology detail (10)

Gene Ontology

Cextracellular space
Fcytokine activity
Fprotein homodimerization activity
Freceptor ligand activity
Pinflammatory response
Pnegative regulation of hemopoiesis
Ppositive regulation of cytokine production involved in inflammatory response
Ppositive regulation of granulocyte macrophage colony-stimulating factor production
Ppositive regulation of interleukin-6 production
Ppositive regulation of interleukin-8 production

202 aa · 22 kDa

Biological roles

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Immune signallingGO

View supporting evidence

Immune signalling

·cytokine activity
·inflammatory response
·positive regulation of cytokine production involved in inflammatory response
·positive regulation of interleukin-6 production

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene IL17D

Gene-level evidence surfaced through the gene IL17D that encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Intelligence

0.12Preliminary

Genetic evidence dominant · Open Targets 0.07

Neoplasms

0.10Preliminary

Literature evidence dominant · Open Targets 0.09 · no direct causal or clinical evidence

Lung carcinoma

0.10Preliminary

Literature evidence dominant · Open Targets 0.08 · no direct causal or clinical evidence

Lung Neoplasms

0.10Preliminary

Literature evidence dominant · Open Targets 0.08 · no direct causal or clinical evidence

Infections

0.10Preliminary

Literature evidence dominant · Open Targets 0.08 · no direct causal or clinical evidence

View evidence synthesis (5)

IntelligencePreliminary

0.12

agreement 0.00–0.24

Genetic100%

Open Targets aggregate 0.07 · 1 independent evidence family

NeoplasmsPreliminary

0.10

agreement 0.00–0.38

Literature100%

Open Targets aggregate 0.09 · 1 independent evidence family · no direct causal or clinical evidence

Lung carcinomaPreliminary

0.10

agreement 0.00–0.38

Literature100%

Open Targets aggregate 0.08 · 1 independent evidence family · no direct causal or clinical evidence

Lung NeoplasmsPreliminary

0.10

agreement 0.00–0.38

Literature100%

Open Targets aggregate 0.08 · 1 independent evidence family · no direct causal or clinical evidence

InfectionsPreliminary

0.10

agreement 0.00–0.37

Literature100%

Open Targets aggregate 0.08 · 1 independent evidence family · no direct causal or clinical evidence

This ranking differs from Open Targets' own: re-weighting moves genetically-evidenced diseases above more heavily co-mentioned ones. The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations

Neoplasms0.09

Lung carcinoma0.08

Lung Neoplasms0.08

Infections0.08

Ovarian carcinoma0.08

Ovarian Neoplasms0.08

Intelligence0.07

Response to antihypertensive drug0.06

Tractability

Antibodies — Emerging

Feasibility evidence (uniprot loc med conf and uniprot sigp or tmhmm) — no clinical-stage drug of this modality recorded.